This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Synthetic Genistein (BONISTEIN™) in Patients Who Are Undergoing Surgery for Prostate Cancer

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified September 2008 by University Hospital, Aker.
Recruitment status was:  Active, not recruiting
Information provided by:
University Hospital, Aker Identifier:
First received: October 17, 2007
Last updated: September 29, 2008
Last verified: September 2008
The purpose of this study is to evaluate safety and mechanisms of possible chemopreventive effects of synthetic genistein (BONISTEIN™) in patients with localized prostate cancer undergoing laparoscopic radical prostatectomy.

Condition Intervention Phase
Prostatic Neoplasms Drug: Genistein Drug: Placebo Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Basic Science
Official Title: Effects of Synthetic Genistein Supplementation on Blood and Tissue Biomarkers in Patients With Localized Prostate Cancer

Resource links provided by NLM:

Further study details as provided by University Hospital, Aker:

Primary Outcome Measures:
  • Modulation of biomarkers: PSA, Testosterone, STAMP1, STAMP2, NKX3A and KLK4, p21, p27, p53, bcl-2, bax, Ki67, CgA and NSE in blood and/or prostate tissue. [ Time Frame: 3 to 6 weeks ]

Secondary Outcome Measures:
  • Modulation of prostate cancer grade, volume and Gleason score. Safety parameters (blood, electrolytes, liver, pancreas, lipids, thyroid and sexual hormones). Plasma and tissue concentrations of BONISTEIN™. [ Time Frame: 3 to 6 weeks ]

Enrollment: 47
Study Start Date: April 2007
Estimated Study Completion Date: January 2009
Primary Completion Date: August 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: 1 Drug: Genistein
Capsule, 30 mg, oral daily for 3 to 6 weeks
Other Name: BONISTEIN™
Placebo Comparator: 2 Drug: Placebo

Detailed Description:
In Norway prostate cancer is the most frequently diagnosed cancer in the male and represents the second most common cause of cancer death among men. Epidemiological studies have shown an association between decreased prostate cancer risk and increased soy consumption. Genistein is the dominating plasma and tissue isoflavone in soybean products, and it has been attributed several anti-cancer effects. BONISTEIN™ is a novel product, consisting of >99,5 % synthetic Genistein aglycone. Chemoprevention is the ability of certain molecules to inhibit (partially or totally) induction or progression of the disease. Our study population consists of men diagnosed with localized prostate cancer who have agreed to undergo radical prostatectomy. This provides adequate amount of benign, premalignant and malignant tissue for studying the effects of potential chemopreventive agents on biomarkers of cell growth and differentiation in the prostatic tissues with immunohistochemistry. Prostatic tissue cells will also be selected with Lacer Capture Microdissection (LCM) before analysis with semi-quantitative RT-PCR.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histological proven prostate cancer clinical stage T1c or T2.
  • Are to be treated by radical prostatectomy 3 to 6 weeks after consent.
  • Have signed the informed consent form.

Exclusion Criteria:

  • Have been on previous or concurrent hormonal therapy or chemotherapy.
  • History of previous or other hormone dependent malignancies.
  • Concomitant thyroid disease or are currently taking thyroid hormone replacement medication.
  • On current high dose soy, micronutrient or herbal supplements.
  • On soy or vegetarian nutrition or have any other extreme dietary habits.
  • On oral anticoagulants.
  • History of liver or pancreas diseases.
  • History of hypersensitivity to Genistein or soy containing products.
  • Have a malabsorption condition which might interfere with absorption of the investigational product.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00546039

Aker University Hospital
Oslo, Norway, 0514
Sponsors and Collaborators
University Hospital, Aker
Study Director: Steinar J Karlsen, MD, PhD Aker University Hospital, Oslo Urological Universityclinic
Principal Investigator: Bato Lazarevic, MD Aker University Hospital, Oslo Urological Universityclinic
  More Information

Additional Information:
Responsible Party: Bato Lazarevic MD, Aker University Hospital Identifier: NCT00546039     History of Changes
Other Study ID Numbers: P2BV10
Study First Received: October 17, 2007
Last Updated: September 29, 2008

Keywords provided by University Hospital, Aker:
Prostate cancer
Localized prostatectomy
Laparoscopic prostatectomy

Additional relevant MeSH terms:
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Genital Diseases, Male
Prostatic Diseases
Anticarcinogenic Agents
Protective Agents
Physiological Effects of Drugs
Antineoplastic Agents
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Estrogens, Non-Steroidal
Hormones, Hormone Substitutes, and Hormone Antagonists processed this record on August 17, 2017